The Safety Profile of Teriflunomide for Multiple Sclerosis Treatment
“This appears to be a very safe and effective drug, and is a valuable part of our therapeutic armamentarium. I don’t think teriflunomide addresses all the unmet needs in MS, in fact, no drug meets all the unmet needs, but this is a very well tolerated oral agent.â€
TOPIC Extension Study: Teriflunomide a "Well Tolerated" Oral Agent for Long-Term Multiple Sclerosis
The nearly 7-year extension trial presented a 47% reduction overall in conversion to clinically definite MS with those patients who had been on 14mg of teriflunomide from the beginning.
What Are The Unmet Needs in ALS Research?
Researchers previously only considered ALS as one illness, but new knowledge has changed that mentality and has shown experts they need to personalize treatment approaches. “It’s important to understand the disease in different groups of people.â€
Frank Conidi: Working Toward a Safer Future in Sports Medicine
Whether it is learning from the military or finding consensus among the governing bodies of youth and scholastic sports there are steps that can be taken to make them safe and help limit the risk of injuries and concussions.
For Robin Williams, Diagnosis Came Too Late
Susan Schneider Williams, spouse of the late Robin Williams spoke with MD Magazine about the several symptoms the actor presented up to a year before his death that made it difficult to diagnose what he was suffering from: Lewy Body Disease (LBD).
Further Analysis of the Benefits of Deflazacort in Patients with Duchenne Muscular Dystrophy
Researchers at the American Academy of Neurology’s 68th Annual Meeting reported analyses of the phase III trial of the investigational glucocorticoid (deflazacort/Marathon Pharmaceuticals), which was previously found to improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.